**Supporting Material – Supplementary tables S1-S5**

Table S1. Descriptive summary of the study variables used.

|  |  |  |
| --- | --- | --- |
| S.No | **Variable** | **Mean ± SD, N** |
| 1 | Sex ratio at birth (SRB) | 1.051 ± 0.02, 94 |
| 2 | Toxoplasmosis prevalence (%) | 33.15±18.82, 94 |
| 3 | Log Wealth  | 3.997± 0.56, 94 |
| 4 | Total fertility | 2.62± 1.34, 94 |
| 5 | Mother age | 26.52± 3.11, 94 |
| 6 | Polygyny intensity | 0.459± 0.32, 94 |
| 7 | Son preference | 0.22± 0.21, 94 |
| 8 | Latitude | 29.31± 17.97, 94 |
| 9 | Parasite stress | 3.12± 0.77, 94 |
| 10 | Nutrition stress | 2.39± 0.42, 94 |
| 11 | Contraceptive use | 56.25± 21.13, 94 |
| 12 | Humidity (%) | 60.48 ± 17.05, 94 |
| 13 | Sanitation rates (%) | 81.07 ± 27.55, 62 |
| 14 | Meat Consumption (grams) | 60.57 ±32.05, 65 |
| 15 | Cat ownership (per capita) | 0.149± 0.37, 62 |

Table S2. Pearson's correlation coefficient matrix of the study variables

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **1** | **2** | **3** | **4** | **5** | **6** | **7** | **8** | **9** | **10** | **11** | **12** | **13** | **14** | **15** |
| **SRB** | 1 | -0.52\*\* | -0.41\*\* | -0.59\*\* | 0.37\*\* | 0.19 | 0.39\*\* | -0.17 | -0.34\*\* | -0.33\*\* | 0.44\*\* | -0.56\*\* | 0.42\*\* | 0.30\* | -0.04 |
| **Parasite stress** | -0.52\*\* | 1 | 0.87\*\* | 0.82\*\* | -0.84\*\* | -0.55\*\* | -0.77\*\* | 0.1 | 0.31\*\* | 0.32\*\* | -0.29\*\* | 0.91\*\* | -0.63\*\* | -0.87\*\* | 0.02 |
| **Nutrition stress** | -0.41\*\* | 0.87\*\* | 1 | 0.76\*\* | -0.82\*\* | -0.46\*\* | -0.68\*\* | 0.06 | 0.30\*\* | 0.31\*\* | -0.09 | 0.82\*\* | -0.60\*\* | -0.84\*\* | 0.02 |
| **Fertility** | -0.59\*\* | 0.82\*\* | 0.76\*\* | 1 | -0.81\*\* | -0.40\*\* | -0.62\*\* | 0.11 | 0.29\*\* | 0.39\*\* | -20.68 | 0.91\*\* | -0.72\*\* | -0.82\*\* | -0.09 |
| **Log wealth** | 0.37\*\* | -0.84\*\* | -0.82\*\* | -0.81\*\* | 1 | 0.55\*\* | 0.66\*\* | -0.12 | -0.40\*\* | -0.16 | 0.2 | -0.87\*\* | 0.61\*\* | 0.90\*\* | 0.03 |
| **Maternal**  | 0.19 | -0.55\*\* | -0.46\*\* | -0.40\*\* | 0.55\*\* | 1 | 0.53\*\* | -0.13 | -0.33\*\* | 0.01 | 0.24\* | -0.49\*\* | 0.23\* | 0.58\*\* | 0.04 |
| **Latitude** | 0.39\*\* | -0.77\*\* | -0.68\*\* | -0.62\*\* | 0.66\*\* | 0.53\*\* | 1 | -0.19 | -0.42\*\* | -0.13 | 0.32\*\* | -0.64\*\* | 0.49\*\* | 0.68\*\* | 0.11 |
| **Humidity** | -0.17 | 0.1 | 0.06 | 0.11 | -0.12 | -0.13 | -0.19 | 1 | 0.24\* | -0.08 | -0.29\*\* | 0.09 | 0.14 | -0.15 | -0.07 |
| **Toxoplasmosis** | -0.34\*\* | 0.31\*\* | 0.30\*\* | 0.29\*\* | -0.40\*\* | -0.33\*\* | -0.42\*\* | 0.24\*\* | 1 | -0.09 | -19.74 | 0.30\*\* | -21.62 | -0.23 | 0 |
| **Polygyny** | -0.33\*\* | 0.32\*\* | 0.31\*\* | 0.39\*\* | -0.16 | 0.01 | -0.13 | -0.08 | -0.09 | 1 | 0.04 | 0.39\*\* | -0.42\*\* | -0.24 | 0.04 |
| **Son preference** | 0.44\*\* | -0.29\*\* | -0.09 | -20.68 | 0.2 | 0.24\* | 0.32\*\* | -0.29\*\* | -19.74 | 0.04 | 1 | -0.26\*\* | 0.05 | 0.13 | -0.03 |
| **Health factor** | -0.56\*\* | 0.91\*\* | 0.82\*\* | 0.91\*\* | -0.87\*\* | -0.49\*\* | -0.64\*\* | 0.09 | 0.30\*\* | 0.39\*\* | -0.26\*\* | 1 | -0.73\*\* | -0.89\*\* | 0.04 |
| **Contraceptive use** | 0.42\*\* | -0.63\*\* | -0.60\*\* | -0.72\*\* | 0.61\*\* | 0.23\* | 0.49\*\* | 0.14 | -21.62 | -0.42\*\* | 0.05 | -0.73\*\* | 1 | 0.61\*\* | 0.01 |
| **Sanitation rate** | 0.30\* | -0.87\*\* | -0.84\*\* | -0.82\*\* | 0.90\*\* | 0.58\*\* | 0.68\*\* | -0.15 | -0.23 | -0.24 | 0.13 | -0.89\*\* | 0.61\*\* | 1 | -0.02 |
| **Cat ownership** | -0.04 | 0.02 | 0.02 | -0.09 | 0.03 | 0.04 | 0.11 | -0.07 | 0 | 0.04 | -0.03 | 0.04 | 0.01 | -0.02 | 1 |
| **Meat con-sumption** | 0.27 | -0.8 | -0.84 | -0.63 | 0.81 | 0.55 | 0.64 | -0.08 | -0.2 | -0.2 | 0.16 | -0.74 | 0.49 | 0.77 | 0.03 |

\* denotes p < .05, \*\* p < .01

Table S3. Categorical regression analysis (CATREG) of sex ratio at birth on toxoplasmosis prevalence and known independent variables for European countries (N = 30).

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Toxoplasmosis prevalence not included** |  | **Toxoplasmosisprevalence (adjusted) included** |  | **Toxoplasmosis prevalence (unadjusted) included** |
| **R2 (adj.)** | .585 (.249) |  | .613 (.298) |  | .607 (.330) |
| **F** | 1.310 |  | 1.411 |  | 1.608 |
| **Δ R2** |  |  | .028 |  | .022 |
| Contraceptive use | -.165\* |  | -.156\* |  | -.157\* |
| Fertility | -.024 |  | -.030 |  | -.029 |
| Health factor | -.049 |  | -.058 |  | -.055 |
| Latitude | -.205\*\*\* |  | -.209\*\*\* |  | -.209\*\*\* |
| Log wealth | -.190\*\*\* |  | -.186\*\*\* |  | -.187\*\*\* |
| Mother age | .101 |  | .094 |  | .100† |
| Nutrition stress | -.057 |  | -.045 |  | -.048 |
| Parasite stress | .089\* |  | .095\* |  | .098\* |
| Polygyny intensity | .059 |  | .066 |  | .065 |
| Son preference | -.048 |  | -.044 |  | -.049 |
| *Toxoplasma* prevalence |  |  | -.086† |  | -.076 |

Δ R2 in the two models in which toxoplasmosis prevalence has been included refers to a change in R2 relative to the model in which the variable has not been included. \* denotes p < .05, \*\* p < .01, and \*\*\* p < .001, † denotes a trend at p < .1.

Table S4. Categorical regression analysis (CATREG) of sex ratio at birth on toxoplasmosis prevalence and known independent variables for non-European countries (N = 64).

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Toxoplasmosis prevalence not included** |  | **Toxoplasmosisprevalence (adjusted) included** |  | **Toxoplasmosis prevalence (unadjusted) included** |
| **R2 (adj.)** | .640 (.547) |  | .660 (.554) |  | .659 (.552) |
| **F** | 5.208\*\*\* |  | 4.685\*\*\* |  | 4.682\*\*\* |
| **Δ R2** |  |  | .020† |  | .019† |
| Contraceptive use | .107\*\*\* |  | .103\*\*\* |  | .101\*\*\* |
| Fertility | -.122\*\*\* |  | -.120\*\*\* |  | -.119\*\*\* |
| Health factor | .099\*\* |  | .095\*\* |  | .094\*\* |
| Latitude | .032 |  | .020 |  | .021 |
| Log wealth | .002 |  | -.008 |  | -.008 |
| Mother age | -.025 |  | -.032 |  | -.027 |
| Nutrition stress | .025 |  | .021 |  | .021 |
| Parasite stress | -.084\* |  | -.087\* |  | -.088\* |
| Polygyny intensity | -.065 |  | -.075 |  | -.075 |
| Son preference | .299\*\* |  | .292\*\* |  | .291\*\* |
| *Toxoplasma* prevalence |  |  | -.092\* |  | -.094\* |

Δ R2 in the two models in which toxoplasmosis prevalence has been included refers to a change in R2 relative to the model in which the variable has not been included. \* denotes p < .05, \*\* p < .01, and \*\*\* p < .001, † denotes a trend at p < .1.

Table S5. Side-by-side comparison of categorical regressions of sex ratio at birth on known confounding factors (excluding son preference) and toxoplasmosis prevalence (both adjusted and unadjusted for mother age), respectively.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Toxoplasmosis prevalence not included** |  | **Toxoplasmosis prevalence (adjusted) included** |  | **Toxoplasmosis prevalence (unadjusted) included** |
| **R2 (adj.)** | .345 (.267) |  | .389 (.307) |  | .387 (.305) |
| **F** | 4.066\*\*\* |  | 4.305\*\*\* |  | 4.280\*\*\* |
| **Δ R2** |  |  | .044\* |  | .042\* |
| Contraceptive use | .065 |  | .062 |  | .061 |
| Fertility | -.156\*\*\* |  | -.153\*\*\* |  | -.153\*\*\* |
| Health factor | .095\*\*\* |  | .086\*\*\* |  | .087\*\*\* |
| Latitude | .057 |  | .043 |  | .046 |
| Log wealth | -.004 |  | -.014 |  | -.014 |
| Mother age | -.011 |  | -.020 |  | -.013 |
| Nutrition stress | -.024 |  | -.022 |  | -.022 |
| Parasite stress | -.098\*\*\* |  | -.098\*\*\* |  | -.099\*\*\* |
| Polygyny intensity | -.090† |  | -.101\*\* |  | -.101\*\* |
| Toxoplasmosisprevalence |  |  | -.117\*\* |  | -.114\*\* |

Δ R2 in the two models in which toxoplasmosis prevalence has been included refers to a change in R2 relative to the model in which the variable has not been included. \* denotes p < .05, \*\* p < .01, † denotes a trend at p < .1.

**References**

**Abu-Madi, M. A., Behnke, J. M. and Dabritz, H. A.** (2010). *Toxoplasma gondii* seropositivity and co-infection with TORCH pathogens in high-risk patients from Qatar. *American Journal of Tropical Medicine and Hygiene,* **82**, 626-633.

**Ashrafunnessa, Shahla, K., Islam, M. N. and Huq, T.** (1998). Seroprevalence of *Toxoplasma* antibodies among the antenatal population in Bangladesh. *Journal of Obstetrics and Gynaecology Research,* **24**.

**Birgisdottir, A., Asbjornsdottir, H., Cook, E., Gislason, D., Jansson, C., Olafsson, I., Gislason, T., Jogi, R. and Thjodleifsson, B.** (2006). Seroprevalence of *Toxoplasma gondii* in Sweden, Estonia and Iceland. *Scandinavian Journal of Infectious Diseases,* **38**, 625-631.

**Bobic, B., Nikolic, A., Klun, I. and Djurkovic-Djakovic, O.** (2011). Kinetics of *Toxoplasma* infection in the Balkans. *Wiener Klinische Wochenschrift,* **123**, 2-6. doi: DOI 10.1007/s00508-011-0052-6.

**Caballero-Ortega, H., Uribe-Salas, F. J., Conde-Glez, C. J., Cedillo-Pelaez, C., Vargas-Villavicencio, J. A., Luna-Pasten, H., Canedo-Solares, I., Ortiz-Alegria, L. B. and Correa, D.** (2012). Seroprevalence and national distribution of human toxoplasmosis in Mexico: analysis of the 2000 and 2006 National Health Surveys. *Transactions of the Royal Society of Tropical Medicine and Hygiene,* **106**, 653-659. doi: 10.1016/j.trstmh.2012.08.004.

**Cantella, R., Colichon, A., Lopez, L., Wu, C., Goldfarb, A., Cuadra, E., Latorre, C., Kanashiro, R., Delgado, M. and Piscoya, Z.** (1974). Toxoplasmosis in Peru. Geographic prevalence of *Toxoplasma gondii* antibodies in Peru studied by indirect fluorescent antibody technique. *Tropical and Geographical Medicine,* **26**, 204-209.

**Contreras, M. C., Schenone, H., Salinas, P., Sandoval, L., Rojas, A., Villarroel, F. and Solis, F.** (2009). Seroepidemiology of human toxoplasmosis in Chile. *Revista do Instituto de Medicina Tropical de Sao Paulo,* **38**, 431-435.

**Crucerescu, E.** (1998). [Epidemiological data on toxoplasmosis. The aspects of congenital toxoplasmosis]. *Bacteriologia, Virusologia, Parazitologia, Epidemiologia,* **43**, 147-155.

**Dubey, J. P., Tiao, N., Gebreyes, W. A. and Jones, J. L.** (2012). A review of toxoplasmosis in humans and animals in Ethiopia. *Epidemiology and Infection,* **140**, 1935-1938. doi: 10.1017/s0950268812001392.

**Elnahas, A., Gerais, A. S., Elbashir, M. I., Eldien, E. S. and Adam, I.** (2003). Toxoplasmosis in pregnant Sudanese women. *Saudi Med J,* **24**, 868-870.

**Fonseca, A. L., Silva, R. A., Fux, B., Madureira, A. P., de Sousa, F. F. and Margonari, C.** (2012). Epidemiologic aspects of toxoplasmosis and evaluation of its seroprevalence in pregnant women. *Revista da Sociedade Brasileira de Medicina Tropical,* **45**, 357-364.

**Joubert, J. J. and Evans, A. C.** (1997). Current status of food-borne parasitic zoonoses in South Africa and Namibia. *Southeast Asian Journal of Tropical Medicine and Public Health,* **28 Suppl 1**, 7-10.

**Kamau, P., Jaoko, W. and Gontier, C.** (2012). Seroepidemiolgy of Toxoplasma gondii in ante-natal women attending Kenyatta National Hospital, Kenya. *International Journal of Infectious Diseases,* **16**, E162-E162. doi: 10.1016/j.ijid.2012.05.697.

**Kistiah, K., Barragan, A., Winiecka-Krusnell, J., Karstaedt, A. and Frean, J.** (2011). Seroprevalence of *Toxoplasma gondii* infection inHIV-positive and HIV-negative subjects in Gauteng,South Africa. *South Afr J Epidemiol Infect,* **26**, 225-228.

**Lafferty, K. D.** (2006). Can the common brain parasite, *Toxoplasma gondii* , influence human culture? *Proceedings of the Royal Society B-Biological Sciences,* **273**, 2749-2755.

**Lindstrom, I., Kaddu-Mulindwa, D. H., Kironde, F. and Lindh, J.** (2006). Prevalence of latent and reactivated Toxoplasma gondii parasites in HIV-patients from Uganda. *Acta Tropica,* **100**, 218-222.

**Liu, Q., Wei, F., Gao, S. Y., Jiang, L., Lian, H., Yuan, B., Yuan, Z. G., Xia, Z. P., Liu, B., Xu, X. H. and Zhu, X. Q.** (2009). *Toxoplasma gondii* infection in pregnant women in China. *Transactions of the Royal Society of Tropical Medicine and Hygiene,* **103**, 162-166.

**Lopes, A. P., Dubey, J. P., Moutinho, O., Gargate, M. J., Vilares, A., Rodrigues, M. and Cardoso, L.** (2012). Seroepidemiology of *Toxoplasma gondii* infection in women from the North of Portugal in their childbearing years. *Epidemiology and Infection,* **140**, 872-877. doi: 10.1017/s0950268811001658.

**Maggi, P., Volpe, A., Carito, V., Schinaia, N., Bino, S., Basho, M. and Dentico, P.** (2009). Surveillance of toxoplasmosis in pregnant women in Albania. *New Microbiologica,* **32**, 89-92.

**Many, A. and Koren, G.** (2006). Toxoplasmosis during pregnancy. *Canadian Family Physician,* **52**, 29-30, 32.

**Mousa, D. A., Mohammad, M. A. and Toboli, A. B.** (2011). *Toxoplasma gondii* infection in pregnant women with previous adverse pregnancy outcome. *Medical Journal of Islamic World Academy of Sciences,* **19**, 95-102.

**Ndumbe, P. M., Andela, A., Nkemnkengasong, J., Watonsi, E. and Nyambi, P.** (1992). Prevalence of infections affecting the child among pregnant women in Yaounde, Cameroon. *Medical Microbiology and Immunology,* **181**, 127-130.

**Pappas, G., Roussos, N. and Falagas, M. E.** (2009). Toxoplasmosis snapshots: Global status of *Toxoplasma gondii* seroprevalence and implications for pregnancy and congenital toxoplasmosis. *International Journal for Parasitology,* **39**, 1385-1394.

**Punda-Polic, V., Tonkic, M. and Capkun, V.** (2000). Prevalence of antibodies to *Toxoplasma gondii* in the female population of the County of Split Dalmatia, Croatia. *European Journal of Epidemiology,* **16**, 875-877.

**Rai, S. K., Shibata, H., Sumi, K., Rai, G., Rai, N., Manandhar, R., Gurung, G., Ono, K., Uga, S., Matsuoka, A., Shrestha, H. G. and Matsumura, T.** (1998). *Toxoplasma* antibody prevalence in Nepalese pregnant women and women with bad obstetric history. *Southeast Asian Journal of Tropical Medicine and Public Health,* **29**, 739-743.

**Sakikawa, M., Noda, S., Hanaoka, M., Nakayama, H., Hojo, S., Kakinoki, S., Nakata, M., Yasuda, T., Ikenoue, T. and Kojima, T.** (2012). Anti-*Toxoplasma* antibody prevalence, primary infection rate, and risk factors in a study of toxoplasmosis in 4,466 pregnant women in Japan. *Clinical and Vaccine Immunology,* **19**, 365-367. doi: 10.1128/cvi.05486-11.

**Sitoe, S. P., Rafael, B., Meireles, L. R., Andrade, H. F., Jr. and Thompson, R.** (2010). Preliminary report of HIV and *Toxoplasma gondii* occurrence in pregnant women from Mozambique. *Revista do Instituto de Medicina Tropical de Sao Paulo,* **52**, 291-295.

**Sukthana, Y.** (2006). Toxoplasmosis: beyond animals to humans. *Trends in Parasitology,* **22**, 137-142.

**Szenasi, Z., Horvath, K., Sarkany, E. and Melles, M.** (2005). Toxoplasmosis surveillance during pregnancy and quality assurance of methods in Hungary. *Wiener Klinische Wochenschrift,* **117**, 29-34. doi: DOI 10.1007/s00508-005-0444-6.

**Szenasi, Z., Ozsvar, Z., Nagy, E., Jeszenszky, M., Szabo, J., Gellen, J., Vegh, M. and Verhofstede, C.** (1997). Prevention of congenital toxoplasmosis in Szeged, Hungary. *International Journal of Epidemiology,* **26**, 428-435.

**Tenter, A. M., Heckeroth, A. R. and Weiss, L. M.** (2000). *Toxoplasma gondii*: from animals to humans. *International Journal for Parasitology,* **30**, 1217-1258.

**Wong, A., Tan, K. H., Tee, C. S. and Yeo, G. S.** (2000). Seroprevalence of cytomegalovirus, *Toxoplasma* and parvovirus in pregnancy. *Singapore Medical Journal,* **41**, 151-155.